Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Primary Human Lungcancer Organoids to Predict Treatment Response

NCT04859166 is registered in ClinicalTrials.gov with Maastricht Radiation Oncology as lead sponsor.

NCT NCT04859166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04859166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Primary Human Lungcancer Organoids to Predict Treatment Response
Lead sponsor
Maastricht Radiation Oncology
Phase
Observational
Overall status
Completed
Start date
November 15, 2017
Completion date
October 1, 2022
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer